Recommended Pages at abstract.asco.org
Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial. | 2011 ASCO Annual Meeting Abstracts
abstract.asco.org — “Search over 4,500 abstracts available for ASCO's 2011 Annual Meeting ? June 3 - 7, 2011 | McCormick Place | Chicago, Illinois” View full resource at abstract.asco.org
Most Recently Shared on June 6, 2011 at 8:36 pm By:
Kidney Cancer Health Executive
Axitinib versus sorafenib as second-line therapy http://bit.ly/iecR21
Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. | 2011 ASCO Annual Meeting Abstracts
abstract.asco.org — “Search over 4,500 abstracts available for ASCO's 2011 Annual Meeting ? June 3 - 7, 2011 | McCormick Place | Chicago, Illinois” View full resource at abstract.asco.org
Most Recently Shared on June 4, 2011 at 9:28 pm By:
Pacific Oncology Physician Group
RT @ASCO: New research identifies the first genetic biomarkers for taxane-induced neuropathy http://ow.ly/5accW #ASCO11
Incidence and characteristics of BRAF V600E mutation in colorectal cancer (CRC) with mismatch repair (MMR) protein defect due to loss of MLH1: A prospective evaluation of 104 consecutive patients. | 2011 ASCO Annual Meeting Abstracts
abstract.asco.org — “Search over 4,500 abstracts available for ASCO's 2011 Annual Meeting ? June 3 - 7, 2011 | McCormick Place | Chicago, Illinois” View full resource at abstract.asco.org
Most Recently Shared on June 4, 2011 at 12:00 pm By:
Summa Health System Healthcare System
Researchers look at BRAF V600E mutation in MLH1 deficient #CRC. Poster on display now at #ASCO11. http://ow.ly/59tV5
Palliative chemotherapy: Does aggressive care beget aggressive care? | 2011 ASCO Annual Meeting Abstracts
abstract.asco.org — “Search over 4,500 abstracts available for ASCO's 2011 Annual Meeting ? June 3 - 7, 2011 | McCormick Place | Chicago, Illinois” View full resource at abstract.asco.org
Most Recently Shared on June 2, 2011 at 5:11 am By:
Robert S. Miller, MD Oncologist, Physician, Doctor, and Internist
T-1d #ASCO11 Abstr # 6127 Palliative chemotherapy: Does aggressive care beget aggressive care? http://bit.ly/mgL1e4
Vitamin D repletion and prevention of bone loss in nonosteoporotic women with breast cancer. | 2011 ASCO Annual Meeting Abstracts
abstract.asco.org — “Search over 4,500 abstracts available for ASCO's 2011 Annual Meeting ? June 3 - 7, 2011 | McCormick Place | Chicago, Illinois” View full resource at abstract.asco.org
Most Recently Shared on May 31, 2011 at 12:28 pm By:
Robert S. Miller, MD Oncologist, Physician, Doctor, and Internist
T-3d #ASCO11 Abstr #9026 Vitamin D repletion & prevention of bone loss in nonosteoporotic women w/ breast cancer http://bit.ly/kmSSff
An evaluation of serum cytokine levels and fatigue and depression in ECOG E4Z02. | 2011 ASCO Annual Meeting Abstracts
abstract.asco.org — “Search over 4,500 abstracts available for ASCO's 2011 Annual Meeting ? June 3 - 7, 2011 | McCormick Place | Chicago, Illinois” View full resource at abstract.asco.org
Most Recently Shared on May 31, 2011 at 12:42 am By:
Robert S. Miller, MD Oncologist, Physician, Doctor, and Internist
T-4d #ASCO11 Abstr #9046 An evaluation of serum cytokine levels and fatigue and depression in ECOG E4Z02. http://bit.ly/m25W31
Gabapentin for the prevention of chemotherapy-induced nausea and vomiting: A pilot study. | 2011 ASCO Annual Meeting Abstracts
abstract.asco.org — “Search over 4,500 abstracts available for ASCO's 2011 Annual Meeting ? June 3 - 7, 2011 | McCormick Place | Chicago, Illinois” View full resource at abstract.asco.org
Most Recently Shared on May 28, 2011 at 1:53 pm By:
Robert S. Miller, MD Oncologist, Physician, Doctor, and Internist
T-6d 'til #ASCO11 Abstr # 9017 Gabapentin for the prevention of chemotherapy-induced nausea and vomiting: A pilot study http://bit.ly/jLwqQB
Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. | 2011 ASCO Annual Meeting Abstracts
abstract.asco.org — “Search over 4,500 abstracts available for ASCO's 2011 Annual Meeting - June 3 - 7, 2011 | McCormick Place | Chicago, Illinois” View full resource at abstract.asco.org
Most Recently Shared on May 19, 2011 at 5:05 pm By:
Our ALN-VSP Phase I clinical trial results on #RNAi Txi for liver cancer published by @ASCO, will be at #ASCO11 June 4: http://goo.gl/l5Tg1
Internet and social media use by patients in a comprehensive cancer center. | 2011 ASCO Annual Meeting Abstracts
abstract.asco.org — “Search over 4,500 abstracts available for ASCO's 2011 Annual Meeting - June 3 - 7, 2011 | McCormick Place | Chicago, Illinois” View full resource at abstract.asco.org
Most Recently Shared on May 18, 2011 at 10:12 pm By:
RT @MaverickNY Still uninspired by #ASCO11 abstracts this year but liked this one: http://bit.ly/kk8s2T social media and cancer patients
Hair depigmentation as an indicator of durable response to CTLA-4 therapy.
abstract.asco.org — “Hair depigmentation as an indicator of durable response to CTLA-4 therapy.” View full resource at abstract.asco.org
Most Recently Shared on June 6, 2010 at 8:31 pm By:
Eric D Whitman, MD Doctor, Surgeon, Oncologist, and Physician
#9 poster IMO: Ipi study correlating hair depig with response. Cool! http://bit.ly/cnWQAU #melanoma #asco10
#7 poster IMO: SPARC microenvironment, another possible way to determine the BEST Rx http://bit.ly/90ayiu #melanoma #asco10
abstract.asco.org — “#7 poster IMO: SPARC microenvironment, another possible way to determine the BEST Rx http://bit.ly/90ayiu #melanoma #asco10” View full resource at abstract.asco.org
Most Recently Shared on June 6, 2010 at 8:22 pm By:
Eric D Whitman, MD Doctor, Surgeon, Oncologist, and Physician
#7 poster IMO: SPARC microenvironment, another possible way to determine the BEST Rx http://bit.ly/90ayiu #melanoma #asco10
Durable response of the triple combination of temozolomide, sorafenib, and bevacizumab to treat refractory stage IV acral melanoma.
abstract.asco.org — “Durable response of the triple combination of temozolomide, sorafenib, and bevacizumab to treat refractory stage IV acral melanoma.” View full resource at abstract.asco.org
Most Recently Shared on June 6, 2010 at 8:19 pm By:
Eric D Whitman, MD Doctor, Surgeon, Oncologist, and Physician
#6 poster IMO: Temodar, avastin, and Nexavar for #melanoma, small study, nice results, deserves F/U http://bit.ly/cOUYtG #asco10
Phase II trial of high-dose interleukin-2 (IL-2) with priming and concomitant sargramostim (GM-CSF) in patients with advanced melanoma.
abstract.asco.org — “Phase II trial of high-dose interleukin-2 (IL-2) with priming and concomitant sargramostim (GM-CSF) in patients with advanced melanoma.” View full resource at abstract.asco.org
Most Recently Shared on June 6, 2010 at 8:15 pm By:
Eric D Whitman, MD Doctor, Surgeon, Oncologist, and Physician
#5 poster IMO: HD IL2 plus GMCSF; good to test but doesn't appear promising http://bit.ly/bzc6du #melanoma #asco10
The use of integrative genomics to define molecular signatures of melanoma histologic subtypes.
abstract.asco.org — “The use of integrative genomics to define molecular signatures of melanoma histologic subtypes.” View full resource at abstract.asco.org
Most Recently Shared on June 6, 2010 at 8:12 pm By:
Eric D Whitman, MD Doctor, Surgeon, Oncologist, and Physician
#4 poster IMO: Integrative genomics differentiates SSM/nodular. how we should decide treatment http://bit.ly/c4NT79 #asco10 #melanoma
Clinico-pathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma.
abstract.asco.org — “Clinico-pathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma.” View full resource at abstract.asco.org
Most Recently Shared on June 6, 2010 at 4:03 pm By:
Eric D Whitman, MD Doctor, Surgeon, Oncologist, and Physician
#1 poster IMO: BRAF expression vs survival in Aust. important early look at this mutation http://bit.ly/bZxjoo #asco10 #melanoma
